NCT Number: NCT02055950
Pulsed Perfusion for Marginal Kidneys
Trends in organ donor pool are characterized by an increasing age and a shift towards cerebrovascular diseases as primary causes of death. As a result, donors older than 60 years nowadays represent more than one fourth of the entire donor pool in Italy. This, along with an increasing number of patients on the waiting list for transplantation, prompted a growing use of organs from subjects older than 60 years that would have been considered unsuitable years ago. To improve graft outcomes, transplant of two older kidneys in the same recipient has been proposed. To optimize allocation of these organs to single or dual transplantation,a scoring system for kidneys, based on biopsy, with scores ranging from a minimum of 0 (indicating the absence of renal lesions) to a maximum of 12 (indicating the presence of marked changes in the renal parenchyma) has been suggested. According to this panel, kidneys with a score of 4 or lower are predicted to contain enough viable nephrons to be used as single transplants, those with a score of 5, 6, or 7 can be used as dual transplants, kidneys with a score greater than 7 are discarded. The survival of kidney grafts obtained from donors older than 60 years and allocated for single or dual transplantation on the basis of biopsy findings before transplantation was similar to that of single grafts from younger donors. To further improve these results, set-up of strategies to preserve organs is crucial to save the residual nephron mass and optimize outcomes of these marginal grafts. In this regard, over the past 30 years two methods of kidney preservation have been developed. With cold storage, the kidney is flushed once it is removed from the donor and placed in an ice-cooled container with preservation solution. With the use of pulsatile machine perfusion, the kidney is connected to a machine, which pumps a cold solution containing oxygen and nutrients through the kidney. This process allows for metabolism to continue in the kidney with end products being removed. The broad aim of the present study is to evaluate whether pulsatile machine perfusion of kidneys from older/marginal donors may provide better outcomes than static perfusion. To this purpose the outcome of recipients of perfused kidneys will be compared with the outcome of historical controls receiving non-perfused kidney selected and allocated on the basis of the same criteria and matched by gender, age and kidney histologic score.
Looking for future studies?
Notify MeKey information
Conditions
Age range
50 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/U.O. Chirurgia Pediatrica, Bergamo, Italy
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Males and females aged 50 years or more and no more than 10 years older or younger than their corresponding donors;
- First single or double kidney transplant from deceased donors older than 60 years;
- Pre-implantation histologic evaluation and graft selection and allocation based on the histologic score and according to the Nord Italian Transplant (NIT) criteria;
- Written informed consent.
Exclusion criteria
- Any factor that according to the NIT selection criteria represent a contraindication to receive a deceased donor kidney transplant
- Need for specific de-sensitization protocols because of high immunological risk (according to NIT criteria) or participation in other concomitant intervention studies
- Vascular abnormalities/changes that preclude the possibility to perfuse the kidney grafts by a pulsatile machine
Treatment and study plan
Kidney perfused by pulsatile machine
ProcedurePrimary outcomes
-
Glomerular filtration rate (GFR)
Time frame: 6 months after transplant.
-
Renal resistance
Time frame: 6 hours after pulsatile machine perfusion
Renal resistance is measured by graft ultrasound. It ranges from 0 to 1.
Secondary outcomes
-
Correlation between renal resistance measured at 6 hours after machine perfusion and renal histological score at pre-transplant biopsy
Time frame: 6 hours after pulsatile machine perfusion
The severity of changes in kidney at pre-transplant biopsy was quantified by a predefined histologic score. Changes in each evaluated component of the kidney tissue , vessels, glomeruli, tubules, and connective tissue, received a score ranging from 0 to 3. The sum of these scores was defined as the global kidney score, which could range from 0 to 12.
Renal resistance is measured by graft ultrasound. It ranges from 0 to 1.
-
Correlation between renal resistances measured at 6 hours after pulsatile machine perfusion and intergraft resistances measured by ultrasound at 7 days and 6 months after transplant.
Time frame: Changes from 7 days at 6 months after transplant .
Renal resistances are measured by graft ultrasound. They range from 0 to 1.
-
Incidence of delayed graft function (DGF).
Time frame: Within the first week after transplant
Sponsors and collaborators
Lead sponsor
Mario Negri Institute for Pharmacological Research
Other
Collaborators
- Fondazione IRCCS Policlinico San Matteo di Pavia
Registry information
Official study title
A PROSPECTIVE STUDY TO COMPARE EARLY GRAFT FUNCTION OF RECIPIENTS OF SINGLE OR DUAL KIDNEY ORGANS STORED IN ICE COLD SOLUTION OR PULSED PERFUSION
Acronym: PREDICTION
Important dates
- Study start
- 2013
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- Feb 5, 2014
- Registry last updated
- Sep 4, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835
Cardiovascular Risk, Chronic Disease
Birmingham, Alabama, United States
View Trial DetailsEffects of Surgical, Percutaneous or Medical Treatments for Coronary Artery Disease on Renal Function: Long-Term Outcome. Cardiorenal-trial.
NCT07195747
Arterial Occlusive Diseases, Arteriosclerosis
São Paulo, Brazil
View Trial DetailsA Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
NCT05254002
Chronic Disease, Chronic Kidney Disease
Surprise, Arizona, United States
View Trial DetailsAssessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study
NCT02579655
Brain Diseases, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial Details